Strategic Japan Partnership for QVITI’s Integrated Neuromodulation Platform

QVITI is a European MedTech company building an integrated platform for neurological and psychiatric therapy. Our ecosystem combines multi-modal transcranial electrical stimulation (tES/tACS), VR-supported therapy, a cloud platform for therapists and a planned therapist-supervised home-care solution.

Our technology has already achieved strong international validation:

• approximately 300 devices in use across 120 institutions in 20 countries;

• 92 devices in Japan across more than 40 institutions;

• users include leading universities and research centres in Japan, the UK, the USA, Canada and Australia;

• a granted patent covering our dry-electrode technology;

• an EU Class IIa legacy medical-device pathway valid through 2028.

We are looking for Japanese partners in:

• medical-device distribution and market access;

• regulatory strategy and certification;

• clinical research and reference-centre development;

• collaborations with hospitals, universities and rehabilitation providers;

• localisation of our digital, VR and home-therapy solutions;

• strategic investment and long-term commercial partnerships.

QVITI offers a differentiated, scalable platform that connects clinic-based therapy, data-supported treatment management and future home care. We would welcome meetings with organisations interested in bringing innovative, evidence-based neurotherapy solutions to the Japanese market.